Korro Bio, Inc. (KRRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $174.45M
Last updated: Nov 17, 2026 at 4:34 PM ET
Korro Bio, Inc. (KRRO) Statistics
Korro Bio (KRRO) has a market cap of $174.45M and an enterprise value of $172.69M. It kept -8214.47% of revenue as net income over the last 12 months. Its share count is up 90.25% from a year earlier.
Total Valuation
Enterprise value is 1.01% below the market cap, as cash exceeds debt.
| Market Cap | $174.45M |
|---|---|
| Enterprise Value | $172.69M |
| Latest price (Nov 17, 2026) | $12.32 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 170.4x and 2.5x.
| P/S Ratio | 170.4x |
|---|---|
| Forward P/S | 178.1x |
| P/B Ratio | 2.5x |
Price Statistics
The stock is up 102.97% over 52 weeks and trades 4.05% above its 50-day average.
| Beta (1Y) | 1.66 |
|---|---|
| 52-Week Change | +102.97% |
| 1-Month Change | +38.27% |
| 3-Month Change | -11.68% |
| 6-Month Change | +34.64% |
| Total Return (1Y) | +102.97% |
| Total Return (3Y CAGR) | -31.88% |
| Return vs SPY (1Y) | +86.51% |
| Max Drawdown (1Y) | -42.32% |
| Max Drawdown (3Y) | -94.13% |
| Sharpe Ratio (1Y) | 0.80 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $11.84 |
| 200-Day Average | $12.16 |
| 52-Week Range | $5.20 to $17.35 |
| RSI (14 Days) | 45.0 |
| Average Volume (20 Days) | 222.30K |
Financial Position
Current assets cover 7.30x current liabilities, and total debt is 0.44x shareholder equity.
| Current Ratio | 7.30x |
|---|---|
| Quick Ratio | 7.30x |
| Debt / Equity | 0.44x |
Returns and Efficiency
Return on invested capital is -82.82% over the last 12 months, against a 5-year average of -92.11%.
| Return on Equity (ROE) | -120.09% |
|---|---|
| Return on Assets (ROA) | -71.65% |
| Return on Invested Capital (ROIC) | -82.82% |
| Return on Capital Employed (ROCE) | -78.85% |
| ROA (5Y Average) | -60.25% |
| ROIC (5Y Average) | -92.11% |
| Asset Turnover | 0.01x |
Scores
KRRO has an Altman Z-Score of -3.52, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -3.52 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $1.29M over the last 12 months is down 82.47% from the 12 months before.
| Revenue | $1.29M |
|---|---|
| Revenue Growth (YoY) | -82.47% |
| Gross Profit | $1.29M |
| Operating Income | -$109.40M |
| Pretax Income | -$105.03M |
| Net Income | -$106.13M |
| EBITDA | -$103.31M |
| EBIT | -$105.03M |
| Reported EPS (TTM) | -$5.39 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 59.66% of the $148.12M in total assets.
| Cash and Equivalents | $40.22M |
|---|---|
| Total Debt | $38.45M |
| Net Cash | $1.76M |
| Net Cash Per Share | $0.10 |
| Working Capital | $94.01M |
| Shareholder Equity | $88.37M |
| Book Value Per Share | $4.95 |
| Total Assets | $148.12M |
| Total Liabilities | $59.75M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $169.00K of capital spending, operating cash flow left -$63.87M of free cash flow.
| Operating Cash Flow | -$63.70M |
|---|---|
| Capital Expenditures | $169.00K |
| Free Cash Flow | -$63.87M |
| FCF Per Share | -$4.34 |
| Depreciation and Amortization | $1.79M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -8467.34%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -8467.34% |
| Pretax Margin | -8129.41% |
| Net Margin | -8214.47% |
| EBITDA Margin | -7996.05% |
| EBIT Margin | -8129.41% |
| FCF Margin | -4943.81% |
Growth
| Revenue Growth (5Y CAGR) | -29.61% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -49.18% |
| Tangible Book Per Share Growth (2Y CAGR) | -49.18% |
Dividends and Yields
KRRO does not pay a dividend. Its free cash flow yield is -29.02%.
| FCF Yield | -29.02% |
|---|---|
| Buyback Yield | -38.74% |
| Shareholder Yield | -38.74% |
Stock Splits
The last split was a 1-for-50 reverse split on Nov 6, 2023.
| Last Split Date | Nov 6, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:50 |
Peer Position
Against 8 similar companies, KRRO has the 2nd highest P/S.
P/S RatioPeer median 6.3x
ROICPeer median -40.30%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +2.54%
| P/S Ratio | 170.4x vs 6.3x median |
|---|---|
| ROIC | -82.82% vs -40.30% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -82.47% vs +2.54% median |
Analyst Forecast
Consensus estimates put revenue growth at -77.02% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -77.02% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About KRRO
What is KRRO's market cap?
Korro Bio has a market cap of $174.45M. Its enterprise value, which adds debt and subtracts cash, is $172.69M.
How many shares of KRRO are outstanding?
Korro Bio has 17.87M shares outstanding. The count is up 90.25% from a year earlier.
Does KRRO pay a dividend?
No. Korro Bio does not pay a dividend.
How much debt does KRRO have?
Korro Bio has $38.45M of total debt and $40.22M of cash and equivalents, a net cash position of $1.76M.
KRRO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors